Cardiac Success pioneers an innovative transcatheter procedure to treat HFrEF patients by directly reshaping the ventricle, halting the cycle of deterioration, reducing heart failure symptoms, and initiating heart recovery.
Cardiac Success pioneers an innovative transcatheter procedure to treat HFrEF patients by directly reshaping the ventricle, halting the cycle of deterioration, reducing heart failure symptoms, and initiating heart recovery.
*References: 1) AHA Heart Disease and Stroke Statistics Update, Circulation 2017; 2) Vedin et al Ischemic Heart Disease in HeartFailure, 2017; 3) Patel et al Journal ofCardiac Failure Vol. 10 No. 4 2004; 4) Cioffiet al. The European Journal of Heart Failure 7, 2005
Heart remodeling therapy: reversing the vicious cycle
Heart Failure with Reduced Ejection Fraction (HFrEF) affects 1.85 million* symptomatic US patients and many more worldwide, despite guideline-directed therapy. With no effective alternatives, their condition often deteriorates due to the vicious cycle of pathological heart remodeling.
Vsling™
Transcatheter ventricular repair device for HFrEF patients
An innovative transcatheter ventricular remodeling solution for heart failure patients. The Vsling is an atraumatic implant, adjustable in size, and delivered via a low-profile delivery system.
Direct treatment of the
failed dilated left
ventricle for currently
untreatable patients
Initiating therapeutic remodeling to reverse
the pathological
process
leveraging surgical ventricular remodeling experience while minimizing complications
Intuitive transcatheter procedure with short
learning curve
Clinical experience
The Vsling, an investigational device, is currently undergoing a focused clinical study in Georgia, Israel, and selected European countries. Early findings suggest its promising role in enhancing patients' quality of life and cardiac function.
Clinical
experience
The Vsling, an investigational device, is currently undergoing a focused clinical study in Georgia, Israel, and selected European countries. Early findings suggest its promising role in enhancing patients' quality of life and cardiac function.
A Case Study
Highlighting the Significant Potential of Vsling Implantation in Treating Heart Failure Patients.
The patient experienced remarkable improvement, which was sustained at the one-year follow-up, substantially improving his overall well-being and quality of life.
Key Inclusion Criteria
- Ejection Fraction ≥ 20% and ≤ 40%
- FMR grade ≤ 2+ (≤ mild)
- NYHA (New York Heart Association) class II-IVa
- LV End Diastolic Diameter ≥ 55 mm
- Cardiomyopathy of ischemic or non-ischemic origins
Key Exclusion Criteria
- Prior mitral valve replacement
- Any evidence of structural mitral lesions
- Severe Aortic stenosis
- Severe Tricuspid regurgitation
A Case Study
A Case Study
Highlighting the significant potential of Vsling implantation in treating heart failure patients.
The patient experienced remarkable improvement, which was sustained at the one-year follow-up, substantially improving his overall well-being and quality of life.
Key Inclusion Criteria
- Ejection Fraction ≥ 20% and ≤ 40%
- FMR grade ≤ 2+ (≤ mild)
- NYHA (New York Heart Association) class II-IVa
- LV End Diastolic Diameter ≥ 55 mm
- Cardiomyopathy of ischemic or non-ischemic origins
Key Exclusion Criteria
- Prior mitral valve replacement
- Any evidence of structural mitral lesions
- Severe Aortic stenosis
- Severe Tricuspid regurgitation
News
Israeli Medical Device Startup, Cardiac Success Ltd., Closes US $5.2M Series A Financing.
Cardiac Success Awarded €10M in Grants and Equity Investment from the European Innovation Council
Cardiac Success Featured at THT 2023 Conference (Technologies and Heart Failure Therapeutics) in Boston.
Our Team
Dr. Shimon Eckhouse
Chairman & Co-Founder
Tami Abudi
VP Clinical & Regulatory Affairs
Dr. Shimon Eckhouse
Chairman & Co-Founder
Boaz Manash
CEO
David Neustadter, PhD
CTO & Founder
Tami Abudi
VP Clinical & Regulatory Affairs
Dr. Shimon Eckhouse
Chairman & Co-Founder
